Pfizer Inc., of New York, said the European Commission approved JAK inhibitor Xeljanz tofacitinib citrate) 5 mg twice daily oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs.